Mogam Institute for Biomedical Research Participates in 'AI Platform for Drug Development' Project

The Mogam Institute for Biomedical Research announced on May 12 that it was selected as a core participating research institution for the national research and development (R&D) project “Establishment and Demonstration of a Multi-Agent AI Platform for the Entire Drug Development Cycle in AI Medicine,” promoted by the Ministry of Science and ICT and the National Research Foundation of Korea on April 27.

The objective of this project is to establish a multi-agent-based AI platform that encompasses the entire drug development cycle, from target discovery to the identification of preclinical candidate substances. The key goal is to create a system in which specialized AI agents, based on large language models (LLMs), autonomously collaborate to make crucial decisions in drug development. Considering the importance of security in the pharmaceutical industry, there are also plans to implement a hybrid system that combines security-specialized on-premises agents capable of handling sensitive data with commercial LLMs.

The Mogam Institute will serve not only as a participant but as a core institution designing the automation of decision-making structures for AI-based drug development throughout the entire cycle. It will be responsible for developing AI agents for the preclinical stage and AI models for target discovery. In collaboration with research labs such as Dr. Lee Kyungryun's Advanced Alternative Testing Team at the Korea Research Institute of Bioscience and Biotechnology, the institute will also develop AI agents based on preclinical pharmacokinetic and drug property data, as well as regulatory response support systems. By implementing a multi-agent coordination framework, the Mogam Institute aims to overcome the current limitations of fragmented, stage-specific AI drug development and contribute to the construction of an integrated, all-cycle platform.

Shin Hyunjin, Director of the Mogam Institute, stated, "This project will become an opportunity to fundamentally reorganize data utilization and decision-making methods throughout the entire drug development cycle, moving beyond the simple application of individual AI models. By presenting a new paradigm for AI-driven drug development based on intelligence throughout the whole cycle, we aim to strengthen the global competitiveness of Korea’s pharmaceutical and biotechnology industries."

This content was produced with the assistance of AI translation services.